Continuous Glucose Monitoring for the Management of Hyperglycemia in Patients With Glioblastoma

Launched by MAYO CLINIC · Jul 21, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at whether using a small device called a continuous glucose monitor (CGM) can help people with glioblastoma—a serious type of brain tumor—better manage their blood sugar levels during treatment. High blood sugar is common in these patients, often because of steroids given to control symptoms, and having high blood sugar during radiation treatment has been linked to shorter survival. The CGM device is worn under the skin and tracks blood sugar levels throughout the day, giving real-time information that can help doctors and patients act quickly to keep sugar levels in a healthy range. The goal is to see if this approach can improve how well patients do overall.

Adults newly diagnosed with a specific type of glioblastoma (called IDH-wildtype, WHO grade 4) may be eligible to join if they are generally well enough to participate, with good blood counts and kidney and liver function. People who have had prior treatments beyond surgery, have certain medical or mental health conditions, or have type 1 diabetes would not qualify. If accepted, participants will use the CGM device and attend sessions for dietary advice as part of the study. This study is not yet recruiting but aims to find a new way to support patients during their cancer treatment by closely watching and managing blood sugar levels.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Histologically confirmed newly diagnosed glioblastoma (World Health Organization \[WHO\] grade IV)
• • IDH-wildtype status confirmed by molecular testing
• • Age ≥ 18 years at the time of consent
• • Karnofsky performance status (KPS) ≥ 70 at baseline
• • Absolute neutrophil count (ANC) ≥ 1.5 × 10\^9/L
• • Platelet count ≥ 100 × 10\^9/L
• • Hemoglobin ≥ 9 g/dL
• • Serum creatinine ≤ 1.5 × upper limit of normal (ULN) or creatinine clearance ≥ 60 mL/min
• • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN
• • Total bilirubin ≤ 1.5 × ULN
• • Willingness and ability to comply with CGM device use and attend dietary counseling sessions as part of the study protocol
• Exclusion Criteria:
• • Recurrent glioblastoma or prior therapy for glioblastoma beyond surgical resection or biopsy
• • History of eating disorders (e.g., anorexia nervosa, bulimia) or substance use disorder within the past 12 months
• • Any other uncontrolled or inadequately managed medical illness (e.g., unstable cardiovascular, hepatic, renal, or psychiatric condition) that, in the opinion of the investigator, would interfere with study participation or interpretation of results
• • Concurrent diagnosis of another active malignancy requiring treatment
• • Pregnancy or breastfeeding at the time of enrollment
• • Documented history of type 1 diabetes mellitus